JP2016521280A - 併用療法を用いて癌を治療する方法 - Google Patents

併用療法を用いて癌を治療する方法 Download PDF

Info

Publication number
JP2016521280A
JP2016521280A JP2016512061A JP2016512061A JP2016521280A JP 2016521280 A JP2016521280 A JP 2016521280A JP 2016512061 A JP2016512061 A JP 2016512061A JP 2016512061 A JP2016512061 A JP 2016512061A JP 2016521280 A JP2016521280 A JP 2016521280A
Authority
JP
Japan
Prior art keywords
compound
lymphoma
cancer
cell
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016512061A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016521280A5 (enExample
Inventor
チョプラ ラジェシュ
チョプラ ラジェシュ
エム．ヘゲ クリステン
エム．ヘゲ クリステン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2016521280A publication Critical patent/JP2016521280A/ja
Publication of JP2016521280A5 publication Critical patent/JP2016521280A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2016512061A 2013-05-03 2014-05-02 併用療法を用いて癌を治療する方法 Pending JP2016521280A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361819384P 2013-05-03 2013-05-03
US61/819,384 2013-05-03
US201361908635P 2013-11-25 2013-11-25
US61/908,635 2013-11-25
PCT/US2014/036520 WO2014179661A1 (en) 2013-05-03 2014-05-02 Methods for treating cancer using combination therapy

Publications (2)

Publication Number Publication Date
JP2016521280A true JP2016521280A (ja) 2016-07-21
JP2016521280A5 JP2016521280A5 (enExample) 2017-06-15

Family

ID=50842385

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016512061A Pending JP2016521280A (ja) 2013-05-03 2014-05-02 併用療法を用いて癌を治療する方法

Country Status (5)

Country Link
US (1) US9119854B2 (enExample)
EP (1) EP2991651A1 (enExample)
JP (1) JP2016521280A (enExample)
TW (1) TW201534305A (enExample)
WO (1) WO2014179661A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020172502A (ja) * 2015-07-02 2020-10-22 セルジーン コーポレイション 血液がん及び固形腫瘍の治療のための併用療法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE035389T2 (en) 2006-09-26 2018-05-02 Celgene Corp 5-substituted quinazolinone derivatives as anticancer agents
RU2611007C2 (ru) 2011-03-11 2017-02-17 Селджин Корпорейшн Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2, 6-диона и их фармацевтические композиции и применение
WO2014039421A1 (en) 2012-09-04 2014-03-13 Celgene Corporation Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2-6-dione and methods of preparation thereof
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US10272083B2 (en) * 2014-01-21 2019-04-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
US20170128448A1 (en) * 2014-07-11 2017-05-11 Celgene Corporation Combination therapy for cancer
WO2016196580A1 (en) * 2015-06-02 2016-12-08 Celgene Corporation Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins
AU2016326499A1 (en) * 2015-09-25 2018-04-12 Celgene Corporation Methods for treating diffuse large B-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs
EP3399980B1 (en) 2016-01-08 2025-07-16 Celgene Corporation Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
TWI782395B (zh) * 2016-01-08 2022-11-01 美商西建公司 抗增生化合物，及其醫藥組合物及用途
US10052315B2 (en) * 2016-01-08 2018-08-21 Celgene Corporation Formulations of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
CA3010794A1 (en) 2016-01-08 2017-07-13 Celgene Corporation Solid forms of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
KR102735378B1 (ko) * 2018-11-09 2024-11-27 한국화학연구원 신규한 피페리딘-2,6-디온 유도체 및 이의 용도
CN113151358B (zh) * 2020-12-31 2024-02-20 洛阳市中心医院（郑州大学附属洛阳中心医院） Znf382稳定转染的弥漫大b细胞淋巴瘤细胞株构建方法及应用
WO2026035999A1 (en) 2024-08-09 2026-02-12 Triana Biomedicines, Inc. Anaplastic lymphoma kinase (alk) degraders and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010504973A (ja) * 2006-09-26 2010-02-18 セルジーン・コーポレーション ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法
JP2010540525A (ja) * 2007-09-26 2010-12-24 セルジーン コーポレイション ６、７又は８置換キナゾリノン誘導体並びにそれらを含有する組成物及びそれらを使用する方法
JP2011526299A (ja) * 2008-06-27 2011-10-06 アビラ セラピューティクス， インコーポレイテッド ヘテロアリール化合物およびそれらの使用
WO2012021444A1 (en) * 2010-08-10 2012-02-16 Avila Therapeutics, Inc. Besylate salt of a btk inhibitor
WO2012125459A1 (en) * 2011-03-11 2012-09-20 Celgene Corporation Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione
WO2012149299A2 (en) * 2011-04-29 2012-11-01 Celgene Corporaiton Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
WO2013063401A1 (en) * 2011-10-28 2013-05-02 Celgene Avilomics Research, Inc. Methods of treating a bruton's tyrosine kinase disease or disorder

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2476166C (en) 2002-02-14 2011-11-15 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
RU2415871C2 (ru) 2005-03-31 2011-04-10 Байомедикс Инк. Моноклональное анти-cd20-антитело
EP1891113A2 (en) 2005-06-02 2008-02-27 AstraZeneca AB Antibodies directed to cd20 and uses thereof
JP5588865B2 (ja) 2007-07-31 2014-09-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｃｄ２０に対するヒト抗体及びその使用方法
US20110243931A1 (en) 2007-09-02 2011-10-06 Thomas Friess Combination therapy with type i and type ii anti-cd20 antibodies
US20120134969A1 (en) 2009-05-25 2012-05-31 Hiroshi Handa Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells
TWI509247B (zh) 2010-03-12 2015-11-21 西建公司 利用雷那度胺（ｌｅｎａｌｉｄｏｍｉｄｅ）治療非霍奇金氏淋巴瘤之方法及作為預測子之基因及蛋白質生物標記

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010504973A (ja) * 2006-09-26 2010-02-18 セルジーン・コーポレーション ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法
JP2010540525A (ja) * 2007-09-26 2010-12-24 セルジーン コーポレイション ６、７又は８置換キナゾリノン誘導体並びにそれらを含有する組成物及びそれらを使用する方法
JP2011526299A (ja) * 2008-06-27 2011-10-06 アビラ セラピューティクス， インコーポレイテッド ヘテロアリール化合物およびそれらの使用
WO2012021444A1 (en) * 2010-08-10 2012-02-16 Avila Therapeutics, Inc. Besylate salt of a btk inhibitor
JP2013533314A (ja) * 2010-08-10 2013-08-22 セルジーン アヴィロミクス リサーチ， インコーポレイテッド Ｂｔｋ阻害剤のベシル酸塩
WO2012125459A1 (en) * 2011-03-11 2012-09-20 Celgene Corporation Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione
JP2014510078A (ja) * 2011-03-11 2014-04-24 セルジーン コーポレイション ３−（５−アミノ−２−メチル−４−オキソ−４ｈ−キナゾリン−３−イル）−ピペリジン−２，６−ジオンを用いる癌の治療方法
WO2012149299A2 (en) * 2011-04-29 2012-11-01 Celgene Corporaiton Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
JP2014514579A (ja) * 2011-04-29 2014-06-19 セルジーン コーポレイション セレブロンを予測因子として使用する癌及び炎症性疾患の治療方法
WO2013063401A1 (en) * 2011-10-28 2013-05-02 Celgene Avilomics Research, Inc. Methods of treating a bruton's tyrosine kinase disease or disorder
JP2014532658A (ja) * 2011-10-28 2014-12-08 セルジーン アヴィロミクス リサーチ， インコーポレイテッド ブルトン型チロシンキナーゼ疾患または障害を治療する方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GANDHI, A.K. ET AL: "CC-122: A pleiotropic pathway modifier with immunomodulatory, antiangiogenic & anticancer activity i", CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA, vol. 13, 1, S179-S180, P-287, JPN6018008084, April 2013 (2013-04-01), ISSN: 0003931128 *
GANDHI, ANITA K., ET AL: "CC-122 is a novel pleiotropic pathway modifier with potent in vitro immunomodulatory and anti-angiog", BLOOD, vol. 120, 21. 2963, JPN6018008083, 2012, ISSN: 0003931127 *
JIANGCHUAN TAO, AACR ANNUAL MEETING 2013, JPN5016005721, 10 April 2013 (2013-04-10), pages 1 - 2, ISSN: 0003931129 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020172502A (ja) * 2015-07-02 2020-10-22 セルジーン コーポレイション 血液がん及び固形腫瘍の治療のための併用療法

Also Published As

Publication number Publication date
US9119854B2 (en) 2015-09-01
TW201534305A (zh) 2015-09-16
WO2014179661A1 (en) 2014-11-06
US20140328832A1 (en) 2014-11-06
EP2991651A1 (en) 2016-03-09

Similar Documents

Publication Publication Date Title
JP6382949B2 (ja) 癌を治療するためのｔｏｒキナーゼ阻害剤及び５−置換キナゾリノン化合物を含む組合せ療法
JP6389241B2 (ja) 癌を治療するためのＴＯＲキナーゼ阻害剤及びＩＭｉＤ化合物を含む組合せ療法
US9119854B2 (en) Methods for treating cancer using combination therapy
US9358232B2 (en) Methods for treating cancer using TOR kinase inhibitor combination therapy
JP2017514806A (ja) Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法
US20140315907A1 (en) Treatment of cancer with dihydropyrazino-pyrazines
JP2017514805A (ja) Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170501

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180306

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181204